Detail akcie Traws Pharma Rg online

Business Summary: Traws Pharma, Inc. is a clinical stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It integrates antiviral drug development, medical intelligence and regulatory strategy in the treatment of viral diseases. The Cadvancing novel investigational oral small-molecule antiviral agents that have potent activity against difficult to treat or resistant virus strains that threaten human health: bird flu and seasonal influenza, and COVID-19/Long COVID. Its four clinical programs consist of Tivoxavir marboxil, Ratutrelvir (TRX0), Narazaciclib, and Rigosertib. Tivoxavir marboxil is a small-molecule cap-dependent endonuclease inhibitor. Ratutrelvir (TRX01) is an inhibitor of the main protease (also known as 3CL protease) of the SARS-CoV-2 virus. arazaciclib is its oral CDK4-plus inhibitor intended initially to treat breast cancers, endometrial and other cancers. Rigosertib is its second asset in oncology.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Traws Pharma Inc revenues increased from $170K to $2.8M. Net income applicable to common stockholders totaled $11.4M vs. loss of $136.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects General And Administrative a decrease of 55% to $3.9M (expense), Research and development decrease of 44% to $5.7M (expense).